Moreover, no new safety concerns were identified for IcoSema in this trial, with the observed safety profile for IcoSema reflecting those of icodec and semaglutide separately [3, 5,6,7, 9,10,11,12, 14, 15]
Masilana A, Khammissa RAG, Lemmer J, Feller J
The slowed gastric emptying that contributes to satiety may also cause prolonged feelings of fullness or discomfort, potentially disrupting normal eating patterns and sleep quality
The complete metabolic and organ baseline before starting GLP-125 markers across blood sugar, insulin, lipids, liver and kidney function
In fact, it significantly increases the risk of adverse outcomes
Retatrutide targets three key hormone receptors GLP-1, GIP, and glucagon making it a unique multi-receptor agonist